Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

1.7K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
1.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery and Development of Voxvoganan: First-in-Class Synthetic Antimicrobial Peptidomimetic.

Journal of medicinal chemistry·2026
Same author

Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma.

Blood·2025
Same author

Pharmacokinetic characterization and exposure-response relationship of crovalimab in the COMMODORE 1, 2 and 3 and COMPOSER trials of patients with paroxysmal nocturnal haemoglobinuria.

British journal of clinical pharmacology·2025
Same author

Quantitative analysis of bone marrow fibrosis highlights heterogeneity in myelofibrosis and augments histological assessment: An Insight from a phase II clinical study of zinpentraxin alfa.

HemaSphere·2024
Same author

Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition.

American journal of hematology·2024
Same author

Genetic Factors in Familial Manifestation of Primary Mediastinal Large B-Cell Lymphoma over Two Generations.

Pathobiology : journal of immunopathology, molecular and cellular biology·2023

Related Experiment Video

Updated: Dec 26, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.5K

[Modern Leukemia Diagnosis].

Pontus Lundberg1, Friedel Wenzel2, Julia Engels3,1

  • 1Diagnostische Hämatologie, Universitätsspital Basel.

Therapeutische Umschau. Revue Therapeutique
|March 12, 2020
PubMed
Summary
This summary is machine-generated.

Modern leukemia diagnosis integrates multiple lab techniques, including cytology, histology, immunophenotyping, and genomic analysis. These methods provide precise diagnoses, prognostic insights, and enable monitoring of residual disease during treatment.

More Related Videos

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.3K
A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model
08:00

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

Published on: October 14, 2016

21.0K

Related Experiment Videos

Last Updated: Dec 26, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.5K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.3K
A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model
08:00

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

Published on: October 14, 2016

21.0K

Area of Science:

  • Hematology
  • Oncology
  • Molecular Diagnostics

Background:

  • Accurate leukemia diagnosis is crucial for effective treatment planning and patient outcomes.
  • Traditional diagnostic methods have limitations in providing comprehensive prognostic information.
  • Advancements in laboratory techniques offer new possibilities for leukemia assessment.

Purpose of the Study:

  • To present an overview of modern, integrative approaches to leukemia diagnosis.
  • To highlight the combination of various laboratory techniques for enhanced diagnostic precision.
  • To emphasize the role of quantitative methods in diagnosis and treatment monitoring.

Main Methods:

  • Morphological cytology and histology for cellular and tissue-level examination.
  • Flow cytometric immunophenotyping for cell surface marker analysis.
  • Genomic analysis, including chromosomal assessment and point mutation detection.

Main Results:

  • Integrative diagnostic strategies combine morphological, immunophenotypic, and genomic data.
  • Quantitative techniques allow for precise diagnosis and prognostic stratification.
  • Residual disease monitoring during treatment is feasible with current methodologies.

Conclusions:

  • Modern leukemia diagnosis is a multi-faceted process integrating diverse laboratory techniques.
  • This integrative approach enhances diagnostic accuracy and provides critical prognostic information.
  • Quantitative analysis enables effective monitoring of treatment response and residual disease.